Blood Screening Market Size & Share, By Product (Reagents & Kits [NAT, ELISA], Instruments), Technology (Serology/Immunoassays, Rapid Test, Western Blot Assays, NGS), End-use (Hospitals, Blood Banks, Pathology Laboratories), Regional Forecast, Industry Players, Growth Statistics Report 2024-2032

Market Outlook:

Blood Screening Market exceeded USD 3.23 Billion in 2023 and is predicted to cross USD 6.14 Billion by end of the year 2032, witnessing more than 7.4% CAGR between 2024 and 2032.

• Base Year Value (2023): USD 3.23 Billion
• CAGR (2024-2032): 7.4%
• Forecast Year Value (2032): USD 6.14 Billion
• Historical Data Period: 2019-2023
• Largest Region: North America
• Forecast Period: 2024-2032

Market Dynamics:

Growth Drivers & Opportunity:

Rising prevalence of infectious diseases and growing demand for blood donations are driving the growth of the blood screening market. Additionally, increasing healthcare spending, technological advancements in blood screening techniques, and expanding awareness about the importance of early disease detection are contributing to market growth.

Report Scope

Report Coverage	Details
Segments Covered	Product, Technology, End-Use
Regions Covered	• North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA)
Company Profiled	Abbott Laboratories, F. Hoffmann-La Roche., Grifols, S.A., Hologic,, QIAGEN N.V., Becton, Dickinson and Company, Bio-Rad Laboratories,, Siemens Healthineers AG, Thermo Fisher Scientific,, SOFINA s.a (Biomerieux), Danaher, Ortho-Clinical Diagnostics,, DiaSorin S.p.A.

Industry Restraints:

The stringent regulations and high cost associated with blood screening tests are major restraints hindering market growth. Moreover, shortage of skilled professionals in the field of blood screening is also impacting market expansion.

Regional Forecast:

North America: The blood screening market in North America is expected to witness steady growth due to the presence of well-established healthcare infrastructure. The United States dominates the market in this region, followed by Canada. Increasing focus on blood safety and rising demand for advanced screening techniques are driving market growth in North America.

Asia Pacific: The blood screening market in Asia Pacific is anticipated to experience rapid growth, primarily driven by countries such as China, Japan, and South Korea. Rising healthcare expenditure, increasing awareness about blood safety, and the presence of a large patient pool are contributing to market growth in this region.

Europe: In Europe, countries like the United Kingdom, Germany, and France are expected to be key contributors to the blood screening market. Stringent regulations regarding blood safety and the presence of advanced healthcare facilities are fueling market growth in these countries. Increasing prevalence of chronic diseases and growing demand for blood transfusions are further driving market growth in Europe.

Segmentation Analysis:

In terms of segmentation, the global Blood Screening market is analyzed on the basis of Product, Technology, End-Use.

Product Analysis

The Blood Screening market is segmented by product into Reagents & Kits (NAT, ELISA) and Instruments. The Reagents & Kits segment is expected to dominate the market due to the increasing prevalence of infectious diseases and the rising demand for blood screening tests. The NAT and ELISA kits offer high sensitivity and specificity, making them the preferred choice for blood screening procedures. On the other hand, the Instruments segment is also poised for growth, driven by the advancements in technology and the increasing adoption of automated screening instruments in healthcare facilities.

Technology Analysis

In terms of technology, the Blood Screening market is segmented into Serology/Immunoassays, Rapid Test, Western Blot Assays, and NGS. Serology/Immunoassays is the most widely used technology for blood screening, owing to its accuracy and reliability in detecting infectious agents in blood samples. However, the Rapid Test segment is gaining traction due to its quick turnaround time and ease of use, especially in point-of-care settings. Moreover, the growing application of NGS technology in blood screening is expected to drive market growth in the coming years.

End-use Analysis

The End-use segment of the Blood Screening market includes Hospitals, Blood Banks, and Pathology Laboratories. Hospitals are the largest end-users of blood screening products and services, primarily due to the high volume of blood screening tests conducted in these facilities. Blood Banks also play a crucial role in the market, ensuring the safety and quality of blood products through rigorous screening protocols. Pathology Laboratories, on the other hand, are witnessing an increasing adoption of advanced blood screening technologies to improve the efficiency and accuracy of screening tests.

Competitive Landscape:

The competitive landscape in the Blood Screening Market is characterized by a mix of established players and emerging companies, all vying to enhance diagnostic accuracy, improve patient outcomes, and reduce testing turnaround times. Key trends include advancements in technology, such as automation and molecular diagnostics, which are driving innovation and increasing efficiency in blood screening processes. Regulatory compliance and the rising awareness of bloodborne diseases further intensify competition, as companies invest in research and development to strengthen their product offerings. Strategic collaborations and mergers are common, allowing firms to expand their market reach and leverage complementary technologies. As the demand for blood screening grows globally, players are focusing on personalized medicine and point-of-care testing to meet the diverse needs of healthcare providers and patients alike.

Top Market Players

- Abbott Laboratories

- Roche Diagnostics

- Siemens Healthineers

- Thermo Fisher Scientific

- BioMerieux

- Ortho Clinical Diagnostics

- Hologic, Inc.

- Grifols S.A.

- PerkinElmer

- Becton, Dickinson and Company